Publications by authors named "Michelle A Baron"

Claim this Profile
C
Comparative Bioavailability of a Novel Solution and a Tablet Formulation of Levothyroxine.
Sunil Vandse, Yannis Psarrakis, Kris Washington, Michelle A Baron

Clin Pharmacol Drug Dev· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA: The FREEDOM-1 HBL (High Baseline) Study.
Robert R Henry, Julio Rosenstock, Douglas S Denham, Prakash Prabhakar, Lise Kjems, Michelle A Baron

Diabetes Care· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial.
Julio Rosenstock, John B Buse, Rehan Azeem, Prakash Prabhakar, Lise Kjems, Michelle A Baron

Diabetes Care· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes.
Robert R Henry, Julio Rosenstock, Douglas Logan, Thomas Alessi, Kenneth Luskey, Michelle A Baron

J Diabetes Complications· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents.
Mary Ann Banerji, Michelle A Baron, Ling Gao, Lawrence Blonde

Postgrad Med· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and risk of hypoglycemia with use of insulin glargine or comparators in patients with cardiovascular risk factors.
Lawrence Blonde, Michelle A Baron, Rong Zhou, Mary Ann Banerji

Postgrad Med· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes.
Robert R Henry, Julio Rosenstock, Douglas K Logan, Thomas R Alessi, Kenneth Luskey, Michelle A Baron

Diabetes Care· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes.
Robert R Henry, Douglas Logan, Thomas Alessi, Michelle A Baron

Clin Ther· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes.
Marc K Israel, Eva Istvan, Michelle A Baron

Vasc Health Risk Manag· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
Julio Rosenstock, James E Foley, Marc Rendell, Mona Landin-Olsson, Jens J Holst, Michelle A Baron

Diabetes Care· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
Julio Rosenstock, Michelle A Baron, Sylvie Dejager, David Mills, Anja Schweizer

Diabetes Care· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin.
John Gerich, Philip Raskin, Lisa Jean-Louis, Das Purkayastha, Michelle A Baron

Diabetes Care· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes.
Edward S Horton, James E Foley, Sharon G Shen, Michelle A Baron

Curr Med Res Opin· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of repaglinide and nateglinide in combination with metformin: response to Raskin et al.
Michelle A Baron

Diabetes Care· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis